As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
Bad Bunny Destroys MAGA Backlash During SNL: “If You Don’t Understand Me, You Have Four Months To Learn”
Take Action Now “All Latinos and Latinas all over the world, and here in the United States, all the people who have worked to open doors. More than…
Senators Launch Bipartisan Bid to Block Trump War on Venezuela
Take Action Now “Congress has not authorized military force against Venezuela,” said Sen. Adam Schiff. “And we must assert our authority to stop the…
Democrats Have Let Republicans Become The “Peace” Party
Take Action Now The massive disconnect between the Democratic Party’s leadership and its base is sure to have ramifications far beyond last year’s…
‘Textbook Authoritarianism’: Trump Aims IRS Criminal Division At Left-Leaning Groups, Donors
Take Action Now Reporting by the Wall Street Journal indicates the active “weaponization” of the agency to target the far-right president’s political…